Silo Pharma Partners with Global CRO for CNS Homing Peptide

Silo Pharma, Inc., a biopharmaceutical company listed on Nasdaq under the ticker SILO, has announced a new collaboration with WuXi AppTec (Hong Kong) Limited for a preclinical study of their innovative CNS homing peptide, SPU-16. Focused on treating multiple sclerosis (MS), Silo Pharma is advancing this therapeutic peptide through a partnership with the University of Maryland, Baltimore.

The forthcoming study aims to evaluate the organ and tissue specificity of the SPU-16 peptide using an experimental autoimmune encephalomyelitis (EAE) model, which is the leading experimental model for MS research. The SPU-16 peptide’s ability to target inflamed epithelial tissues indicates its potential as a focused drug delivery mechanism for spinal cord inflammation.

Eric Weisblum, CEO of Silo Pharma, expressed enthusiasm about the study stating, "We are excited to launch this new study of our novel CNS homing peptide under the management of WuXi AppTec, one of the largest CROs in Asia and globally." Weisblum highlighted that SPU-16 is engineered to cross the blood-brain barrier and specifically target damaged tissue and inflammation. This peptide could enhance the effectiveness of both existing and new therapeutics while reducing their toxicity. While the current focus is on MS, Weisblum believes that SPU-16 could offer similar advantages for other neuroinflammatory conditions.

Multiple sclerosis is a prevalent inflammatory demyelinating disease affecting young adults and is one of the most common disabling neurological disorders. The global market for MS drugs is expected to grow significantly, from $21.2 billion in 2024 to $38.9 billion by 2032, with a compound annual growth rate (CAGR) of 7.9%.

Silo Pharma Inc. is a developmental stage biopharmaceutical company that specializes in creating innovative treatments for various underserved conditions, including stress-induced psychiatric disorders, chronic pain, and CNS diseases. The company is actively developing both traditional drugs and psychedelic therapies in unique formulations and delivery systems. 

Silo's leading program, SPC-15, is an intranasal treatment designed for PTSD and stress-induced anxiety disorders. Another promising project, SP-26, involves a time-release ketamine-loaded implant intended for the relief of fibromyalgia and chronic pain. Additionally, Silo is working on two preclinical programs: SPC-14, an intranasal compound aimed at treating Alzheimer’s disease, and SPU-16, the CNS-homing peptide targeting MS. The company’s research efforts are conducted in collaboration with universities and independent laboratories.

Silo Pharma's ongoing initiatives reflect a commitment to developing groundbreaking treatments that address significant medical needs. The partnership with WuXi AppTec for the preclinical study of SPU-16 represents a crucial step in potentially offering new therapeutic options for patients suffering from multiple sclerosis and neuroinflammatory diseases.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!